Drugs / Lucanisatuzumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07258108 | Nov 2025 → Jul 2027 expected | breast cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lucanisatuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07258108 ↗ |
| Route | Intravenous | “Each participant receives Lucanisatuzumab plus tagolimumab intravenously.” NCT07258108 ↗ |